药物重新定位
重新调整用途
药物开发
临床试验
机制(生物学)
医学
药品
药物发现
医学教育
工程伦理学
风险分析(工程)
药理学
计算机科学
制药工业
作者
C. Glenn Begley,Mark R. Ashton,Jonathan B. Baell,Michael Bettess,Michael P. Brown,Brett Carter,William N. Charman,Christopher Davis,Simon Fisher,Ian H. Frazer,Anand Gautam,Michael P. Jennings,Philip Kearney,Eloise Keeffe,Darren J. Kelly,Angel F. Lopez,Michael A. McGuckin,Michael W. Parker,Craig Rayner,Brett Roberts,James S. Rush,Mark Sullivan
标识
DOI:10.1126/scitranslmed.abd5524
摘要
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often, however, there is insufficient consideration by academic researchers of the processes required to ensure that a repurposed drug can be used for a new indication. This may explain the inability of drug repurposing to fulfill its promise. Important aspects, often overlooked, include financial and intellectual property considerations, the clinical and regulatory path, and clinical equipoise, which provides ethical justification for randomized controlled trials. The goal of drug repurposing is to obtain a new regulator-approved label for an existing drug, and so, the trajectory for drug repurposing and traditional drug development is similar. Here, we discuss factors critical for a successful repurposed medicine to help academic investigators better identify drug repurposing opportunities.
科研通智能强力驱动
Strongly Powered by AbleSci AI